Australia - English - Department of Health (Therapeutic Goods Administration)

pierre fabre australia pty ltd - vinorelbine tartrate, quantity: 27.7 mg (equivalent: vinorelbine, qty 20 mg) - capsule, soft - excipient ingredients: ethanol; purified water; glycerol; macrogol 400; gelatin; iron oxide yellow; titanium dioxide; medium chain triglycerides; ascorbyl palmitate; phosphatidyl choline; dl-alpha-tocopherol; sorbitol; 1,4-sorbitan; mannitol; hydrogenated starch hydrosylate; hypromellose; propylene glycol; isopropyl alcohol; aluminium chloride; sodium hydroxide; cochineal - non-small cell lung cancer: navelbine oral is indicated for first line treatment of advanced non-small cell lung cancer, as a single agent or in combination.,breast cancer: navelbine oral is indicated for the treatment of advanced breast cancer after failure of standard therapy as a single agent or in combination.

Australia - English - Department of Health (Therapeutic Goods Administration)

pierre fabre australia pty ltd - vinorelbine tartrate, quantity: 13.85 mg/ml (equivalent: vinorelbine, qty 10 mg/ml) - injection, concentrated - excipient ingredients: water for injections - navelbine is indicated for the treatment of advanced breast cancer after failure of standard therapy, as a single agent or in combination; and as first line treatment for advanced non-small cell lung cancer, as a single agent or in combination. navelbine is indicated for the treatment, in combination with cisplatin, of patients with completely resected non-small cell lung cancer of stage ib or greater.

Australia - English - Department of Health (Therapeutic Goods Administration)

pierre fabre australia pty ltd - vinorelbine tartrate, quantity: 13.85 mg/ml (equivalent: vinorelbine, qty 10 mg/ml) - injection, concentrated - excipient ingredients: water for injections - navelbine is indicated for the treatment of advanced breast cancer after failure of standard therapy, as a single agent or in combination; and as first line treatment for advanced non-small cell lung cancer, as a single agent or in combination. navelbine is indicated for the treatment, in combination with cisplatin, of patients with completely resected non-small cell lung cancer of stage ib or greater.

United States - English - NLM (National Library of Medicine)

pierre fabre usa inc. - hydroquinone (unii: xv74c1n1ae) (hydroquinone - unii:xv74c1n1ae) - glytone skin lightening cream is indicated for the gradual lightening of hyperpigmented skin conditions such as chloasma, melasma, freckles, senile lentigines, and other unwanted areas of melanin hyperpigmentation. prior history of sensitivity or allergic reaction to this product or any of its ingredients. the safety of topical hydroquinone use during pregnancy or in children (12 years and under) has not been established.

United States - English - NLM (National Library of Medicine)

pierre fabre usa inc. - hydroquinone (unii: xv74c1n1ae) (hydroquinone - unii:xv74c1n1ae), avobenzone (unii: g63qqf2nox) (avobenzone - unii:g63qqf2nox), octinoxate (unii: 4y5p7mud51) (octinoxate - unii:4y5p7mud51), octocrylene (unii: 5a68wgf6wm) (octocrylene - unii:5a68wgf6wm), oxybenzone (unii: 95oos7ve0y) (oxybenzone - unii:95oos7ve0y) - glytone sunvanish is indicated for the gradual lightening of hyperpigmented skin conditions such as chloasma, melasma, freckles, senile lentigines, and other unwanted areas of melanin hyperpigmentation. prior history of sensitivity or allergic reaction to this product or any of its ingredients. the safety of topical hydroquinone use during pregnancy or in children (12 years and under) has not been established.

United States - English - NLM (National Library of Medicine)

pierre fabre usa inc. - hydroquinone (unii: xv74c1n1ae) (hydroquinone - unii:xv74c1n1ae) - glytone skin lightening gel is indicated for the gradual lightening of hyperpigmented skin conditions such as chloasma, melasma, freckles, senile lentigines, and other unwanted areas of melanin hyperpigmentation. prior history of sensitivity or allergic reaction to this product or any of its ingredients. the safety of topical hydroquinone use during pregnancy or in children (12 years and under) has not been established.

Ireland - English - HPRA (Health Products Regulatory Authority)

pierre fabre medicament - vinorelbine - concentrate for solution for infusion - 10 milligram(s)/millilitre - vinca alkaloids and analogues; vinorelbine

Australia - English - Department of Health (Therapeutic Goods Administration)

pierre fabre australia pty ltd - encorafenib, quantity: 75 mg - capsule, hard - excipient ingredients: magnesium stearate; copovidone; iron oxide black; gelatin; iron oxide red; iron oxide yellow; poloxamer; titanium dioxide; crospovidone; colloidal anhydrous silica; microcrystalline cellulose; succinic acid - melanoma,encorafenib, in combination with binimetinib, is indicated for the treatment of adult patients who have unresectable or metastatic melanoma with a braf v600e or v600k mutation, as detected by a validated test.,colorectal cancer,encorafenib, in combination with cetuximab, is indicated for the treatment of adult patients who have metastatic colorectal cancer (mcrc) with a braf v600e mutation as detected by a validated test, and who have received prior systemic therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

pierre fabre australia pty ltd - encorafenib, quantity: 50 mg - capsule, hard - excipient ingredients: magnesium stearate; copovidone; iron oxide black; gelatin; iron oxide red; iron oxide yellow; poloxamer; titanium dioxide; crospovidone; colloidal anhydrous silica; microcrystalline cellulose; succinic acid - melanoma,encorafenib, in combination with binimetinib, is indicated for the treatment of adult patients who have unresectable or metastatic melanoma with a braf v600e or v600k mutation, as detected by a validated test.,colorectal cancer,encorafenib, in combination with cetuximab, is indicated for the treatment of adult patients who have metastatic colorectal cancer (mcrc) with a braf v600e mutation as detected by a validated test, and who have received prior systemic therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

pierre fabre australia pty ltd - binimetinib, quantity: 15 mg - tablet, film coated - excipient ingredients: iron oxide black; macrogol 3350; colloidal anhydrous silica; purified talc; iron oxide yellow; microcrystalline cellulose; polyvinyl alcohol; magnesium stearate; titanium dioxide; croscarmellose sodium; lactose monohydrate - binimetinib in combination with encorafenib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a braf v600e or v600k mutation, as detected by a validated test.